SGLT2 inhibitor use reduces end-stage kidney disease in patients with transthyretin amyloid cardiomyopathy
Current assessment
Synthesis pending
Confidence
Not assessed
Supporting evidence (0)
Nothing recorded on this side
Contradicting evidence (0)
Nothing recorded on this side
Discussion (0)
Sign in to join the discussion.
No comments yet
Be the first to weigh in on this evidence.